Comparison of gastrointestinal side effects from different doses of azithromycin for the treatment of gonorrhoeaShow others and affiliations
2022 (English)In: Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, E-ISSN 1460-2091, Vol. 77, no 7, p. 2011-2016Article in journal (Refereed) Published
Abstract [en]
OBJECTIVES: Azithromycin is commonly used to treat Neisseria gonorrhoeae. We compared its gastrointestinal side effects using 1 g single, 2 g single or 2 g split (i.e. 1 g plus 1 g 6-12 h later) dosing, representing our clinic's changing guidelines over the study period.
METHODS: We recruited consecutive sexual health clinic patients who received azithromycin (and 500 mg ceftriaxone) for uncomplicated gonorrhoea. Each patient received a text message 48 h after their attendance to complete a questionnaire.
RESULTS: Patients received 1 g single (n = 271), 2 g single (218) or 2 g split (105) doses. Vomiting was less common for 1 g versus 2 g single dose [1.1% versus 3.7%; risk difference (RD): -2.6%; 95% CI: -0.2 to -5.4] and 2 g split versus 2 g single dose (0.9% versus 3.7%; RD: -2.8%; 95% CI: -0.3 to -5.8). Nausea was less common for 1 g versus 2 g single dose (13.7% versus 43.1%; RD: -29.5%; 95% CI: -21.7 to -37.2) and 2 g split versus 2 g single dose (16.4% versus 43.1%; RD: -26.8; 95% CI: -17.2 to -36.3). Diarrhoea was less common for 1 g versus 2 g single dose (25.5% versus 50.9%; RD: -25.5%; 95% CI: -17.0 to -33.9) and 2 g split versus 2 g single dose (30.9% versus 50.9%; RD: -20.0; 95% CI: -9.1 to -30.9). Almost all were willing to retake the same dosing for gonorrhoea in the future: 97% for 1 g single; 94% for 2 g single; and 97% for 2 g split dose.
CONCLUSIONS: Azithromycin 2 g split dose for gonorrhoea resulted in significantly less vomiting, nausea and diarrhoea than a 2 g single dose.
Place, publisher, year, edition, pages
Oxford University Press, 2022. Vol. 77, no 7, p. 2011-2016
National Category
Infectious Medicine
Identifiers
URN: urn:nbn:se:oru:diva-98557DOI: 10.1093/jac/dkac118ISI: 000786045000001PubMedID: 35411400Scopus ID: 2-s2.0-85133214010OAI: oai:DiVA.org:oru-98557DiVA, id: diva2:1651701
Note
Funding agency:
National Health and Medical Research Council (NHMRC) of Australia GNT1193955 GNT1172873 GNT1172900 GNT1136117
2022-04-132022-04-132022-08-22Bibliographically approved